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Abstract 
Background: Women exposed to Plasmodium infection develop antibodies and become semi‑immune. This immu‑
nity is suppressed during pregnancy making both the pregnant woman and the foetus vulnerable to the adverse 
effects of malaria, particularly by Plasmodium falciparum. Intermittent preventive treatment of malaria in pregnancy 
(IPTp) with Sulfadoxine–pyrimethamine (SP) tablets is one of the current interventions to mitigate the effects of 
malaria on both the pregnant woman and the unborn child. The extent to which IPTp may interfere with the acquisi‑
tion of protective immunity against pregnancy‑associated malaria (PAM) is undefined in Ghana.
Methods: Three‑hundred‑and‑twenty pregnant women were randomly enrolled at the antenatal clinic (ANC) in 
Madina, Accra. Venous blood samples were obtained at first ANC registration and at 4‑week intervals (post‑IPTp 
administration). Placental and cord blood samples were obtained at delivery and the infants were followed monthly 
for 6 months after birth. Anti‑IgG and IgM antibodies against a crude antigen preparation and the glutamate‑rich 
protein (GLURP) of P. falciparum were quantified by the enzyme‑linked immunosorbent assay (ELISA).
Results: There was a general decline in the trend of mean concentrations of all the antibodies from enrolment to 
delivery. The levels of antibodies in cord blood and placenta were well correlated. Children did not show clinical signs 
of malaria at 6 months after birth.
Conclusions: IgG against both crude antigen and GLURP were present in placenta and cord blood and it is there‑
fore concluded that there is a trend of declining antibody from enrolment to delivery and IPTp‑SP may have reduced 
malaria exposure, however, this does not impact on the transfer of antibodies to the foetus in utero. The levels of 
maternal and cord blood antibodies at delivery showed no adverse implications on malaria among the children at 
6 months. However, the quantum and quality of the antibody transferred needs further investigation to ensure that 
the infants are protected from severe episodes of malaria.
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Background
About 50 million women who become pregnant in 
malaria-endemic regions each year [1] are infected with 
Plasmodium parasite [2]. Pregnant women are three times 
more likely to suffer from severe disease from malarial 
infection than their non-pregnant counterparts, with close 
to 50% mortality rate from severe disease [3]. Malaria, par-
ticularly Plasmodium falciparum infection increases the 
risk of maternal anaemia and other complications in preg-
nancy, often leading to abortions and stillbirths [4].
In general, immunity to P. falciparum develops slowly 
and naturally [5, 6] after repeated exposure [7–10]. The 
acquired anti-Plasmodium antibodies confer protective 
immunity [11], which reduces morbidity [12–14]. How-
ever, clinical immunity to malaria is partial and short-
lived, and requires constant ‘longitudinal exposure’ to 
parasites to be maintained [9].
Despite acquiring partial immunity after years of expo-
sure to Plasmodium, pregnant women become highly 
susceptible to P. falciparum due to the absence of immu-
nity to pregnancy-specific isolates that sequester in 
the placenta [2, 15] resulting in long-standing placental 
malaria even when peripheral blood may be negative for 
malaria parasites, especially during the second trimester 
[16].
The parasites that infect the placenta have a spe-
cial affinity to accumulate in the erythrocytes in the 
blood spaces of the placenta [17] and also characteristi-
cally bind to the placental ligand, chondroitin sulfate A 
(CSA) [18, 19]. A protective anti-CSA antibody-mediated 
immunity to pregnancy-associated malaria (PAM) devel-
ops after repeated exposure of the placenta to parasites. 
The multigravidae, who have developed anti-CSA from 
previous exposure, are less susceptible to PAM than the 
primigravidae who are experiencing the placenta for the 
first time [20, 21]. PAM can affect placenta development 
and function, leading to deleterious outcome to both 
mother and her infant [22–24], which further increases 
the risk for neonatal and infant mortality [25, 26]. Infec-
tion of the placenta by malaria parasites has been found 
to have no effect on the transmission of maternal anti-
bodies to infants [27].
Another reason for the high susceptibility of pregnant 
women is attributed to various hormonal and immuno-
logical changes during pregnancy, with a leaning from 
cell-mediated immunity to humoral immunity. Primi-
gravidae have higher levels of cortisol than multigravi-
dae and therefore lose their acquired immunity more 
frequently and this increases their susceptibility to P. 
falciparum infection. These problems are more common 
in the first and second pregnancies since the parasitae-
mia level generally decreases with increasing numbers 
of pregnancies. In Ghana, malaria during pregnancy 
increases maternal anaemia and low birth weight (LBW), 
especially in women living in rural communities [28–30].
Newborn infants in endemic areas are markedly resist-
ant to falciparum malaria due to protection from high 
levels of maternal anti-malarial immunoglobulin G (IgG) 
passively transferred across the placenta [31]. Congeni-
tal malaria is therefore rare in endemic areas but infants 
may present with parasitaemia within 2–3 months as the 
maternal acquired antibodies wane [32]. There is there-
fore a gradual acquisition of IgG to variant surface anti-
gens (VSAs) after birth, while protection from maternal 
VSA-specific IgG steadily declines [33]. These antibodies, 
against a broad range of variant antigens, are important 
for protection against febrile malaria episodes in children 
who are in the process of acquiring malaria immunity 
[13]. Severe disease is therefore rare during the first few 
months of life [16].
The use of intermittent preventive treatment of malaria 
in pregnancy (IPTp) has been shown to increase birth 
weight and reduce the incidence of LBW [34] as well as 
reduce pregnancy-related parasitaemia and anaemia [35–
40]. Regardless of these benefits, there is concern that “any 
exposure-reducing interventions could result in the loss of 
or failure to acquire protective (PAM) immunity” [41–43] 
which would increase the overall, long-term disease bur-
den [44] by increasing morbidity and mortality [45, 46]. 
The use of IPTp with Sulfadoxine–pyrimethamine (SP) 
treatment of primigravidae has also been shown to reduce 
levels of plasma IgG, which protects against pregnancy-
associated falciparum malaria [47, 48] and severe malaria 
among children [49]. However, the extent to which IPTp 
may interfere with acquisition of protective immunity 
against PAM is largely undefined, particularly in Ghana. 
The present study was designed to evaluate the effect of 
IPTp on antibody-mediated immunity against malaria 
during pregnancy. This study further sought to determine 
whether IPTp disrupts the transfer of maternal antibod-
ies across the placenta. Specific concentrations of IgG and 
immunoglobulin M (IgM) antibodies against a glutamate-
rich protein (GLURP) and crude antigen (Ag) preparation 
were obtained from pregnant women from enrolment to 
delivery and from cord blood of the infants.
Methods
Study setting
The study was conducted at the Alpha Medical Hospital 
in Madina, a densely populated and fast-growing, peri-
urban area in the Ga-East Municipality of Accra, south-
ern Ghana. This study was a sub-component of a larger 
study that looked at IPTp implementation in the Ga-East 
Municipality of Accra. The full details of the study setting 
and characteristics of the participants are described in 
Stephens et al. [50].
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Study participants
The study participants were selected from all pregnant 
women making their first visit for antenatal care at the 
Alpha Medical Centre from July to August regardless of 
ethnic or socio-economic background, gestation, par-
ity or gravid status. The inclusion criteria were pregnant 
women who indicated their intention to deliver at the 
facility and who had not previously taken IPTp for their 
current pregnancy.
Study procedure
Briefly, pregnant women who met the inclusion crite-
ria were invited to volunteer to participate in the study. 
Socio-demographic information was collected by ques-
tionnaire, as well as information on gravidity, parity, the 
use of IPTp, insecticidal-treated nets (ITNs), drug seek-
ing behaviour, and other anti-malarial practices during 
pregnancy. Gestation was estimated from abdominal 
examination by qualified midwives and confirmed later 
by scan. A venous blood sample was obtained at first 
registration for general screening and for plasma analy-
sis to determine pre-IPTp antibody status. Women who 
were eligible for IPTp administration were served by 
hospital staff at monthly intervals. Blood samples were 
then obtained 4 weeks after each IPTp administration to 
determine their post-IPTp P. falciparum antibody titre. 
Placenta and cord blood samples were also collected at 
delivery. Infants born to these women were followed at 
monthly intervals for 6 months. The body temperature of 
the infants was determined at each visit. Follow-up was 
facilitated by the use of mobile phones.
Blood sampling
Venous blood was collected into 5-ml  K3EDTA vacu-
tainer tubes with butterfly needles (Becton–Dickinson 
Vacutainer Systems, UK) by a qualified phlebotomist. 
Each tube was labelled with the subject’s unique identi-
fication number and stored in a cool box. Samples were 
transferred to the laboratory at the University of Ghana, 
Legon for further analysis. Whole blood samples were 
centrifuged at 2000 revolutions per minute (rpm) using 
a Spectrafuge (Labnet International, Inc, Edison, NJ, 
USA) and the plasma was carefully collected and stored 
at −40 °C for anti-malaria antibody assays. The resulting 
pellet of red cells were washed twice and then cryopre-
served in glycerolyte solution at −40 °C.
Maternal intervillous blood (IVB) was obtained at deliv-
ery by a modified placental prick method as described by 
Othoro et  al. [51]. An experienced technician accessed 
the placental intervillous spaces through the chorionic 
plate after delivery. The placenta was carefully placed on 
a raised sterile wire mesh stand, with the chorionic plate 
facing downward to facilitate blood accumulation and 
IVB space. A large-bore, 14-gauge needle attached to a 
syringe was directed approximately 0.5 cm deep through 
the wire mesh into the intervillous space, denoted as dark 
purple regions, taking care to avoid puncturing the sur-
rounding fetal vessels on the surface of the chorionic 
plate. The syringe was gently pulled to create a vacuum 
and initiate blood flow. The needle was withdrawn to col-
lect a 5-ml sample into a previously labelled micro cen-
trifuge tube charged with 25  μl of a 1:4 heparin (stock 
concentration, 1000 units/ml) dilution in phosphate-
buffered saline (PBS). The procedure was repeated to col-
lect cord blood. The samples were stored in a refrigerator 
at the maternity unit and transferred in a cool box to the 
laboratory for further processing. Birth weight of each 
infant was recorded by the delivering midwife.
Antibody analysis
Antibodies against two antigens, a specific blood-stage 
antigen of P. falciparum or GLURP, and a soluble crude 
antigen preparation from whole blood-stage parasites 
were determined as previously described [52]. Briefly, 
96-well micro titre plates (Immulon 2 HBX) were coated 
(100 μl/well) at 1 μg/ml for GLURP and 5 × 105 cells/well 
for crude antigen in plain PBS. The plates were incubated 
overnight at 4 °C, retrieved, washed four times with PBS/
Tween 20, then incubated with 200  μl/well of blocking 
buffer (3% skimmed milk in 1X PBS) for 1 h at room tem-
perature in a humidified chamber. The plates were washed 
as described and 100 ul of plasma pre-diluted at 1:2000 
in 1% PBS/milk was added in duplicates to each well and 
incubated for 2 h as described. To control for inter-assay 
variations in the procedure, each assay plate included a 
pool of hyper immune plasma known to be positive for 
total IgG to GLURP and the schizont extract, diluted at 
1:500. To the plates were then added 100 μl/well of 0.5 μg/
ml peroxidase labelled goat anti-human IgG (H + L) con-
jugate (KPL), and peroxidase-labelled goat anti-human 
IgM at 0.5 μg/ml for 1 h at room temperature for the IgG 
and IgM respectively and incubated for 1  h. Plates were 
developed with 100 μl/well 3,3′ 5,5′ tetramethylbenzidine 
(TMB) substrate for 30 min in the dark. After incubation 
the reaction was stopped with 100  μl 0.2  M  H2SO4 and 
optical density (OD) was read at 450 um with a reference 
wavelength of 630 um using a spectrophotometer (Vmax 
Kinetic micro plate reader-Molecular Devices Corpora-
tion, CA, USA). Optical density values were converted to 
concentrations using a 4-parameter curve fit using pure 
human IgG and IgM standards fitted on each plate.
Ethical considerations
Ethical clearance for the study was obtained from the 
Institutional Review Board (IRB) of the Noguchi Memo-
rial Institute for Medical Research, College of Health 
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Sciences, University of Ghana, Legon (Study Number: 
004/06-07). An informed consent was obtained from 
each volunteer and assent was documented by signing or 
by thumb printing the consent form.
Statistical analysis
Responses to the questionnaire were numerically coded 
on paper and later transferred into an electronic data-
base. Responses and laboratory results were entered into 
a computer in Epi Info version 3.5. The data were then 
cleaned and verified. Data summaries (frequencies and 
distributions) were examined. Participants were grouped 
by gravidity and by gestation at registration. The mean 
values for various parameters, such as antibody levels, 
use of bed nets and the number of IPTp doses adminis-
tered for various categories of pregnant women, were 
compared using standard parametric and non-paramet-
ric statistical methods using the SPSS and EPI info statis-
tical software.
For normally distributed data, comparisons between 
means and percentages were done by Students’ t test, 
ANOVA and Fisher’s exact tests as appropriate at P < 0.05 
significant level. Multivariate regression was performed 
with the number of IPTp doses taken and antibody titre 
against age, parity and gestation.
Limitations
Some limitations are acknowledged. First, HIV sta-
tus is important in antibody reduction but data were 
not collected and therefore were not investigated in 
the present study. Second, it was not possible to exam-
ine the association between malaria antibody levels and 
bed nets due to the low usage of ITNs. Third, although 
malaria transmission is seasonal with a peak during the 
rainy season (July to September), the very low prevalence 
of malaria, reported in an earlier study [50] among the 
pregnant women, limited the ability to assess seasonality 
effects.
Results
A total of 320 pregnant women were enrolled in the 
study. The details of the characteristics of the study par-
ticipants have been reported in [50]. In brief, the mean 
gestation at registration and onset of IPTp uptake were 
18.5 and 23.5  weeks, respectively. Peripheral blood 
parasitaemia and placental positivity were 5 and 2.5%, 
respectively. There were 37.8% (121/320) deliveries in the 
hospital. One-hundred-and-twenty-one paired placenta 
and cord blood was obtained at delivery. The rest of the 
women either did not deliver in the hospital as they had 
indicated and a few were missed at the time of delivery. 
The mean concentrations of antibodies against IgG and 
IgM are shown in Figs. 1 and 2, respectively.
The mean concentrations of IgG against GLURP 
decreased from the baseline to post IPT1 and slightly 
increased after IPT2, dropped after IPT3 and plateaued, 
but imposition of trend lines showed a sharp decrease in 




























Fig. 1 Mean crude and GLURP concentrations of IgG among pregnant women of all parities after IPTp from enrolment to delivery
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the crude malaria parasite Ag was lower than IgG against 
GLURP at baseline (pre-IPTp) but increased after the 
first dose of IPT (IPT1) and then declined until after 
IPT2 and then decreased at delivery (placental blood) 
(Fig. 1). The trend lines showed a general decrease. The 
mean antibody concentrations of IgG against crude Ag 
were significantly higher than the corresponding concen-
tration of anti-GLURP IgG throughout pregnancy, except 
at baseline (P < 0.01).
The mean concentrations of anti-GLURP IgM antibod-
ies were higher than those of the anti-crude IgM anti-
bodies at baseline and after IPT1 but the levels reversed 
after IPT2 and after IPT3 and again at delivery. The lev-
els of IgM antibodies against both Crude Ag increased 
then decreased after IPT3 but the general trend showed 
a decrease in both. IgM GLURP also showed a general 
decrease from post-IPTp1 (Fig.  2). Concentrations of 
anti-GLURP IgM antibodies were significantly higher 
than concentration of anti-crude IgM antibodies at base-
line but reversed at delivery (P = 0.01).
The concentrations by parity are shown in Figs.  3, 4, 
5 and 6. Analysis of the differences between the mean 
plasma concentrations of antibodies (IgG and IgM) 
against the two malaria parasite antigens in primigravi-
dae and multigravidae showed no significant differences. 
There were significant differences for the mean antibody 
values of both IgM crude and IgM GLURP (P =  0.01) 
but no significant differences between IgG crude and 
IgG GLURP (P  =  0.195). Majority 96.7% (117/121) of 
the babies delivered weighed at least 2.5  kg. Of the few 
women 3.3% (4/121) who delivered babies with birth 
weight less than 2.5 kg, two had taken one dose and the 
other two had taken two doses of IPT. The data showed 
that one of them was a primigravida, two were mul-
tigravidae and the gravid status of the fourth person 
was unknown. Among those who delivered babies of at 
least 2.5 kg, 7.7% (9/117) had not received any IPT dur-
ing pregnancy, while 46.2% (54/117) received the three 
doses of IPT, which was the maximum number of rec-
ommended doses at the time of the study. A significant 
correlation was found between the number of IPTp doses 
taken and the weight of the baby at delivery (P = 0.024). 
There was also a strong positive correlation between anti-




















































Fig. 3 Comparison of IgG GLURP concentration by parity among 
pregnant women on IPTp
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Anti-GLURP IgG levels declined from baseline to 
delivery for the primigravida while mean concentra-
tions among the multigravida declined at baseline but 
the level increased after IPTp2 and then decreased after 
IPTp3 (Fig. 3). Both anti-GLURP IgG and IgM concentra-
tions for the multigravida were higher than those for the 
primigavida except at IPTp3 where the levels for the mul-
tigravida dropped remarkably (Figs. 3, 4).
Discussion
In the present study, GLURP was used as pure antigen 
together with a crude antigen preparation containing 
many antigens. Generally, although the IgG antibody lev-
els against the crude P. falciparum antigen were found to 
be significantly higher than those against GLURP, both 
have been found to correlate with protection against 
malaria [53, 54]. The concentrations of both antibodies 
showed a decline with IPTp uptake probably as a result 
of decay in antibodies or as a result of the clearance of 
parasitaemia by treatment with SP. This is consistent with 
other studies [43, 48, 55, 56], which also found a decline 
in the levels of antibodies against several antigens during 
pregnancy and after delivery. The decrease in antibody 
levels is believed to be linked with pregnancy-specific 
malaria immunity rather than to non-pregnancy associ-
ated malaria antigens [48] as speculated elsewhere [50] or 
possibly to short-lived responses in the absence of infec-
tion [43, 55].
HIV-infected pregnant women are known to also 
exhibit low levels of antibodies to P. falciparum antigens 
[57, 58] but this study did not collect information on HIV 
status of the study participants and therefore was unable 
to find any linkage for the low levels of IgG among the 
study participants. Again, previous malaria episodes have 
been demonstrated to be associated with increased anti-
body levels [59] but this was not explored in the present 
study. Another interesting factor associated with failure 
to acquire protective PAM immunity is exposure-reduc-
ing interventions [41]. Exposure to ITN interventions 
either early or later in pregnancy have also been shown to 
reduce malaria immunity but ITN usage among the study 
participants was very low (5%) as reported in an earlier 
study [50]. Analysis of the effect of the ITN use on the 
antibody levels could not be done due to the low num-
bers. Antibody levels could also be affected by seasonal 
change [60] or any particular pregnancy [61, 62] but 
there was a general decline among the pregnant women 
who were recruited at the beginning of the study and 
those recruited later as the recruitment period was short 
(July to August) and there was minimum or no variation 
in the season.
Although there were differences expected in par-
ity of the women, both primigravidae and multigravidae 
showed a decline in antibody levels in support of the low 
prevalence rate. Another factor of interest is the plasma 
volume expansion associated with pregnancy, which 
might contribute to the overall decrease in antibody lev-
els, attributed to low or lack of exposure [56]. A virtual 
anaemia is caused by an increase in circulating blood 
plasma. As a result, there are fewer red blood cells per ml 
of plasma compared to the blood of the non-pregnant, 

























Fig. 4 Comparison of IgM GLURP concentration by parity among 

























Fig. 5 Comparison of crude IgG concentration by parity among 
























Fig. 6 Comparison of crude IgM concentrations by parity among 
pregnant women on IPTp
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diluted and less concentrated in antibodies. Until recently 
this physiological phenomenon has been taken to mean 
that the pregnant woman is anaemic and therefore mean 
corpuscular volume (MCV) is a more accurate measure of 
anaemia. Nevertheless, a comparison with the above stud-
ies shows low anaemia rates for the women in the present 
study population [50]. This is supported by reports of a 
study in a rural district in Ghana with anaemia prevalence 
rate of 57.1% (haemoglobin (Hb)  <10  g/dl) among preg-
nant women. The study concluded that anaemia was more 
prevalent among rural pregnant women than those in the 
urban areas of the same district (P = 0.01) [29].
The low prevalence of moderate and severe anaemia is 
supported by the finding of low prevalence of peripheral 
blood parasitaemia. Contrary to earlier studies, malaria 
among pregnant women living in areas of malaria has 
been reported to be symptomatic [5, 63]. Another study 
in an area of high and intense malaria transmission has 
shown the overall prevalence of malaria among women 
attending ANC to be about 47% with anaemia rate of 72% 
(Hb < 11 g/dl) and severe anaemia rate of 2% (Hb < 7 g/
dl) [64]. This still underscores the fact that malaria 
remains the major cause of maternal anaemia in Madina 
and therefore programmes and policies aimed at the con-
trol of anaemia in pregnant women in Madina should 
focus primarily on malaria.
The peaks of IgM and IgG antibody levels post-IPT1, 
also around the second trimester, may indicate increased 
susceptibility to malaria, which usually occurs in the 
second trimester [28, 65]. The presence of IgM suggests 
that the women were still infected despite the IPTp they 
were receiving during pregnancy or that the parasites 
were possibly resistant to SP to some degree [66]. How-
ever, SP-IPTp has recently been shown to clear parasitae-
mia in asymptomatic women [67]. The steady decline in 
anti-IgM against both crude antigen and GLURP from 
baseline and after each dose of IPTp towards delivery 
may reflect the lower exposure to malaria, since infection 
and intra-erythrocytic replication of parasites is required 
for the induction of these antibodies. This shows that 
any methods which either reduce exposure to mosquito 
bites, such as bed nets or interrupts erythrocytic repli-
cation of the parasites, such as anti-malarials, can effec-
tively reduce antibody levels against blood-stage antigens 
as shown by the present study. The decline in IgG levels 
shown in this study has also been reported [47] and may 
reflect the use of IPTp. However, since the threshold for 
protection of these antibodies against malaria were not 
established in the present study it is impossible to deter-
mine whether these women were rendered susceptible to 
malaria as a result of IPTp use.
The lower levels of anti-crude IgM antibodies in multi-
gravidae as compared to primigravidae, reflects possible 
sub-microscopic parasitaemia carriage in primigravidae. 
This reflects new infections which could mean that most 
of the primigravidae might have experienced current 
infections compared to multigravidae, which is inconcert 
with the literature.
IgG against the crude antigen and GLURP were pre-
sent in both placenta and cord blood even though the 
mean concentrations in cord blood were less than in 
the placenta, as found in other studies [68, 69]. A possi-
ble explanation is that in women with placental malaria, 
the anti-malarial antibodies bind to malaria antigen and 
become trapped in the placenta as immune complexes 
[70]. Further, the lower antibody levels in cord blood may 
be due to the thickening of the placental membranes as 
a result of malaria infection [71], a condition which may 
serve as a barrier to the efficient transfer of maternal pro-
teins in a more generalized manner and which is similar 
to what happens with the transfer of low levels of anti-
tetanus antibodies by women with placental malaria [72]. 
However, in the present study peripheral blood parasi-
taemia was only 5%, while placental malaria was present 
in samples examined (2.5%) [50]. Future studies should 
include other non-malarial antigens, including measles 
antigen, to provide better understanding of trans-placen-
tal transfer of maternal antibody.
There are presently no specific quantities of malaria 
antibodies that correlate with clinical protection [73] and 
therefore it is not possible to state whether or not the 
antibody concentrations in the cord blood were enough 
to offer protection to the infants born to study partici-
pants. Children with particularly high levels of antibodies 
at birth can remain antibody positive (in the absence of 
active immunization by infection) up to 11  months but 
in Ghana the median duration of maternal antibodies 
to a crude P. falciparum schizont extract was 14  weeks 
[74]. Maternal antibody falls to minimal levels by the 
4th month of life while infant antibody titres began to 
rise from about 6 months of age, following active immu-
nization by exposure [75]. Newborn infants in endemic 
areas are markedly resistant to falciparum malaria due 
to high levels of anti-malarial IgG passively transferred 
across the placenta. Consequently, severe disease is rare 
during the first few months of life, and infections tend to 
be low density and relatively asymptomatic during this 
period. However, congenital parasitaemia may present 
2–3  months after delivery when maternal antibodies 
wear off [16].
There are conflicting views about the protection con-
ferred on infants by maternal antibodies with the major-
ity of the studies concluding that despite the small 
numbers in their respective studies, maternal antibod-
ies do protect infants from clinical malaria and high 
parasitaemia irrespective of the presence or absence of 
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maternally derived antibody, but do not protect infants 
from malaria infection, most of whom are asymptomatic 
[76]. There is also evidence for an association between 
decreasing levels of maternally derived, malaria-specific 
IgG and increasing risk of clinical malaria at a population 
level, but the numbers of children in most of the studies 
were not large enough to provide any convincing analysis 
[71]. The small numbers of children born to the study is 
a challenge. Women gave their consent to participate in 
the study and were recruited based upon their delivery 
at the hospital. However, socio-cultural practices made 
about 60% of them deliver outside the study-designated 
facility. They could not be replaced because the study was 
time bound. The study also provided a delivery package 
as incentive and participants received priority consulta-
tion at the ANC.
None of the children in the present study registered 
hyperpyrexia (body temperature  >36.5  °C) during the 
post-natal follow-up to justify the collection of blood 
samples as per the approved protocol. There are many 
reasons attributed to protection in childhood. These 
range from the biting habits of anopheline mosquitoes 
that have preference to for blood of adults and older chil-
dren, to protection by breast milk constituents. Others 
are the physiologic barrier by foetal haemoglobin (HbF), 
resulting in the delay of parasite development and pro-
tection from severe illness [32]. The introduction of IPTp 
has recently been shown to be associated with increased 
risk of severe malaria among infants [45]. This has serious 
implications for the use IPTp and raises questions about 
the passive transfer of antibodies across the placenta as 
well as the quality and quantities transferred.
Conclusions
The study concludes that intermittent preventive treat-
ment reduces immunoglobulin G levels among pregnant 
women on IPTp due to the low prevalence of parasitae-
mia. The children born to the mothers were protected 
for 6 months and showed no clinical symptoms after fol-
low-up and thus IPTp allowed the transfer of antibodies 
across the placenta. Future studies should look into other 
non-malarial antigens to provide better understanding of 
antibody transfer.
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